Month-Long Postoperative Radiotherapy and 5-FU Improve Survival in Rectal Cancer

OncologyONCOLOGY Vol 10 No 9
Volume 10
Issue 9

A month of postoperative radiotherapy preceded by radiosensitizing boluses of fluorouracil (5-FU) slashed the recurrence rate and markedly improved survival in patients with Dukes B and C rectal cancer in a study from the Norwegian Adjuvant Rectal Cancer Project Group, presented at the European Cancer Conference (ECCO-8).

A month of postoperative radiotherapy preceded by radiosensitizingboluses of fluorouracil (5-FU) slashed the recurrence rate andmarkedly improved survival in patients with Dukes B and C rectalcancer in a study from the Norwegian Adjuvant Rectal Cancer ProjectGroup, presented at the European Cancer Conference (ECCO-8).

"The effect is comparable to more prolonged, resource-demanding,and toxic regimens, such as the 6-month and 18-month regimensused in the United States today," said Dr. K. M. Tveit ofthe Norwegian Radium Hospital, Oslo.

He called the regimen "a good alternative that can be recommendedin patients with a high probability of local recurrence and ininstitutions where the local recurrence rate with surgery aloneis relatively high--more than 10%."

Subjects randomized to the experimental arm of this 144-patienttrial received 23 fractions of 2 Gy with a three-field technique,starting 4 to 6 weeks after surgery. Patients were treated inthe prone position with a full bladder to minimize toxicity tothe bowel.

In an attempt to achieve an optimal interaction between fluorouraciland radiation, fluorouracil doses of 500 or 750 mg were administered30 minutes before radiotherapy fractions 1, 2, 11, 12, 21, and22.

Five-year relapse-free survival reached 64% in patients who underwentadjuvant therapy, compared with 46% in the surgery-alone patients,Dr. Tveit reported. Five-year overall survival was 64% in theadjuvant therapy group and 49% in the control group.

The incidence of local recurrences, most of which were associatedwith distant metastases, was only 12% in the adjuvant therapyarm vs 30% in the control group, he said.

Except for three cases of grade 3 dermatitis, adjuvant therapywas well tolerated, Dr. Tveit said, emphasizing that there wasno excess incidence of small bowel obstruction in the adjuvanttherapy group.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content